# SEQUENCE LISTING

(1)     GENERAL INFORMATION:

(i)     APPLICANT:  GREENE, ET AL.

(ii)    TITLE OF INVENTION:     Human Tumor Necrosis Factor
                                Receptor

(iii)   NUMBER OF SEQUENCES:  9

(iv)    CORRESPONDENCE ADDRESS:

        (A)  ADDRESSEE:  CARELLA, BYRNE, BAIN, GILFILLAN,
                         CECCHI, STEWART & OLSTEIN
        (B)  STREET:  6 BECKER FARM ROAD
        (C)  CITY:     ROSELAND
        (D)  STATE:    NEW JERSEY
        (E)  COUNTRY: USA
        (F)  ZIP:       07068

(v)     COMPUTER READABLE FORM:
        (A) MEDIUM TYPE:  3.5 INCH DISKETTE
        (B) COMPUTER:  IBM PS/2
        (C) OPERATING SYSTEM:  MS-DOS
        (D) SOFTWARE:  WORD PERFECT 5.1

(vi)    CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER:
        (B) FILING DATE: Concurrently
        (C) CLASSIFICATION:

(vii)   PRIOR APPLICATION DATA
        (A)  APPLICATION NUMBER: PCT/US95/03216
        (B)  FILING DATE:  15 MAR 1995

```
(viii) ATTORNEY/AGENT INFORMATION:
       (A) NAME:  FERRARO, GREGORY D.
       (B) REGISTRATION NUMBER:  36,134
       (C) REFERENCE/DOCKET NUMBER:  325800-381


(ix)   TELECOMMUNICATION INFORMATION:
       (A) TELEPHONE:  201-994-1700
       (B) TELEFAX:    201-994-1744


  (2)  INFORMATION FOR SEQ ID NO:1:


  (i)  SEQUENCE CHARACTERISTICS
       (A) LENGTH:  1173 BASE PAIRS
       (B) TYPE:  NUCLEIC ACID
       (C) STRANDEDNESS:  SINGLE
       (D) TOPOLOGY:  LINEAR


 (ii)  MOLECULE TYPE:  cDNA


 (xi)  SEQUENCE DESCRIPTION:  SEQ ID NO:1:


ATGAACAAGT TGCTGTGCTG CGCGCTCGTG TTTCTGGACA TCTCCATTAA GTGGACCACC       60
CAGGAAACGT TTCCTCCAAA GTACCTTCAT TATGACGAAG AAACCTCTCA TCAGCTGTTG      120
TGTGACAAAT GTCCTCCTGG TACCTACCTA AAACAACACT GTACAGCAAA GTGGAAGACC      180
GTGTGCGCCC CTTGCCCTGA CCACTACTAC ACAGACAGCT GGCACACCAG TGACGAGTGT      240
CTATACTGCA GCCCCGTGTG CAAGGAGCTG CAGTACGTCA GCAGGAGTG CAATCGCACC      300
CACAACCGCG TGTGCGAATG CAAGGAAGGG CGCTACCTTG AGATAGAGTT CTGCTTGAAA      360
CATAGGAGCT GCCCTCCTGG ATTTGGAGTG GTGCAAGCTG GAACCCCAGA GCGAAATACA      420
GTTTGCAAAA GATGTCCAGA TGGGTTCTTC TCAAATGAGA CGTCATCAA AGCACCCTGT      480
AGAAAACACA CAAATTGCAG TGTCTTTGGT CTCCTGCTAA CTCAGAAAGG AAATGCAACA      540
CACGACAACA TATGTTCCGG AAACAGTGAA TCAACTCAAA AATGTGGAAT AGATGTTACC      600
CTGTGTGAGG AGGCATTCTT CAGGTTTGCT GTTCCTACAA AGTTTACGCC TAACTGGCTT      660
AGTGTCTTGG TAGACAATTT GCCTGGCACC AAAGTAAACG CAGAGAGTGT AGAGAGGATA      720
AAACGGCAAC ACAGCTCACA AGAACAGACT TTCCAGCTGC TGAAGTTATG GAAACATCAA      780
AACAAAGACC AAGATATAGT CAAGAAGATC ATCCAAGATA TTGACCTCTG TGAAAACAGC      840
GTGCAGCGGC ACATTGGACA TGCTAACCTC ACCTTCGAGC AGCTTCGTAG CTTGATGGAA      900
AGCTTACCGG GAAAGAAAGT GGGAGCAGAA GACATTGAAA AAACAATAAA GGCATGCAAA      960
CCCAGTGACC AGATCCTGAA GCTGCTCAGT TTGTGGCGAA TAAAAAATGG CGACCAAGAC     1020


                                  -45-
```

```
ACCTTGAAGG GCCTAATGCA CGCACTAAAG CACTCAAAGA CGTACCACTT TCCCACAAAC   1080
TGTCACTCAG AGTCTAAAGA AGACCATCAG GTTCCTTCAC AGCTTCACAA TGTACAAATT   1140
GTATCAGAAG TTATTTTTAG AAATGATAGG TAA                                1173
```

(2)    INFORMATION FOR SEQ ID NO:2:

  (i)   SEQUENCE CHARACTERISTICS

     (A)  LENGTH:  390 AMINO ACIDS

     (B)  TYPE:   AMINO ACID

     (C)  STRANDEDNESS:

     (D)  TOPOLOGY:  LINEAR


  (ii)          MOLECULE TYPE:  PROTEIN


  (xi) SEQUENCE DESCRIPTION:  SEQ ID NO:2:


```
Met Asn Lys Leu Leu Cys Cys Ala Leu Val Phe Leu Asp Ile Ser
    -20                -15                -10

Ile Lys Trp Thr Thr Gln Glu Thr Phe Pro Pro Lys Tyr Leu His
    -5                  1               5

Tyr Asp Glu Glu Thr Ser His Gln Leu Leu Cys Asp Lys Cys Pro
10                  15                20

Pro Gly Thr Tyr Leu Lys Gln His Cys Thr Ala Lys Trp Lys Thr
25                  30                35

Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr Asp Ser Trp His
40                  45                50

Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys Lys Glu Leu
55                  60                65

Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg Val Cys
70                  75                80

Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu Lys
85                  90                95

His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala Gly Thr
100                 105               110

Pro Glu Arg Asn Thr Val Cys Lys Arg Cys Pro Asp Gly Phe Phe
115                 120               125
```

```
Ser Asn Glu Thr Ser Ser Lys Ala Pro Cys Arg Lys His Thr Asn
130             135             140
Cys Ser Val Phe Gly Leu Leu Leu Thr Gln Lys Gly Asn Ala Thr
145             150             155
His Asp Asn Ile Cys Ser Gly Asn Ser Glu Ser Thr Gln Lys Cys
160             165             170
Gly Ile Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg Phe Ala
175             180             185
Val Pro Thr Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val Asp
190             195             200
Asn Leu Pro Gly Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile
205             210             215
Lys Arg Gln His Ser Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys
220             225             230
Leu Trp Lys His Gln Asn Lys Asp Gln Asp Ile Val Lys Lys Ile
235             240             245
Ile Gln Asp Ile Asp Leu Cys Glu Asn Ser Val Gln Arg His Ile
250             255             260
Gly His Ala Asn Leu Thr Phe Glu Gln Leu Arg Ser Leu Met Glu
265             270             275
Ser Leu Pro Gly Lys Lys Val Gly Ala Glu Asp Ile Glu Lys Thr
280             285             290
Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile Leu Lys Leu Leu Ser
295             300             305
Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr Leu Lys Gly Leu
310             315             320
Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe Pro Thr Asn
325             330             335
Cys His Ser Glu Ser Lys Glu Asp His Gln Val Pro Ser Gln Leu
.340            345             350
His Asn Val Gln Ile Val Ser Glu Val Ile Phe Arg Asn Asp Arg
355             360             365
```

(2)    INFORMATION FOR SEQ ID NO:3:

(i)     SEQUENCE CHARACTERISTICS
        (A) LENGTH:  33 BASE PAIRS
        (B) TYPE:  NUCLEIC ACID
        (C) STRANDEDNESS:  SINGLE
        (D) TOPOLOGY:  LINEAR

(ii)    MOLECULE TYPE:  Oligonucleotide

(xi)    SEQUENCE DESCRIPTION:  SEQ ID NO:3:

    GCCAGAGGAT CCGAAACGTT TCCTCCAAAG TAC                     33

    (2)    INFORMATION FOR SEQ ID NO:4:

(i)     SEQUENCE CHARACTERISTICS
        (A) LENGTH:  33 BASE PAIRS
        (B) TYPE:  NUCLEIC ACID
        (C) STRANDEDNESS:  SINGLE
        (D) TOPOLOGY:  LINEAR

(ii)    MOLECULE TYPE:  Oligonucleotide

(xi)    SEQUENCE DESCRIPTION:  SEQ ID NO:4:

    CGGCTTCTAG AATTACCTAT CATTTCTAAA AAT                     33

    (2)    INFORMATION FOR SEQ ID NO:5:

(i)     SEQUENCE CHARACTERISTICS
        (A) LENGTH:  31 BASE PAIRS
        (B) TYPE:  NUCLEIC ACID
        (C) STRANDEDNESS:  SINGLE
        (D) TOPOLOGY:  LINEAR

(ii)    MOLECULE TYPE:  Oligonucleotide

(xi)    SEQUENCE DESCRIPTION:   SEQ ID NO:5:

GCGCGGATCC ATGAACAAGT TGCTGTGCTG C                                31

(2)    INFORMATION FOR SEQ ID NO:6:

(i)    SEQUENCE CHARACTERISTICS
       (A) LENGTH:   34 BASE PAIRS
       (B) TYPE:   NUCLEIC ACID
       (C) STRANDEDNESS:   SINGLE
       (D) TOPOLOGY:   LINEAR

(ii)   MOLECULE TYPE:   Oligonucleotide

(xi)   SEQUENCE DESCRIPTION:   SEQ ID NO:6:

GCGCTCTAGA TTACCTATCA TTTCTAAAAA TAAC                             34

(2)    INFORMATION FOR SEQ ID NO:7:

(i)    SEQUENCE CHARACTERISTICS
       (A) LENGTH:   31 BASE PAIRS
       (B) TYPE:   NUCLEIC ACID
       (C) STRANDEDNESS:   SINGLE
       (D) TOPOLOGY:   LINEAR

(ii)   MOLECULE TYPE:   Oligonucleotide

(xi)   SEQUENCE DESCRIPTION:   SEQ ID NO:7:

GCGCGGTACC TCAGTGGTTT GGGCTCCTCC C                                31

(2) INFORMATION FOR SEQ ID NO:8:

(i)    SEQUENCE CHARACTERISTICS

(A) LENGTH: 39 BASE PAIRS

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

(ii)     MOLECULE TYPE: Oligonucleotide

(xi)     SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCCAGAGGAT CCGCCACCAT GAACAAGTTG CTGTGCTGC          39

(2)     INFORMATION FOR SEQ ID NO:9:

(i)     SEQUENCE CHARACTERISTICS

(A) LENGTH: 60 BASE PAIRS

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: SINGLE

(D) TOPOLOGY: LINEAR

(ii)     MOLECULE TYPE: Oligonucleotide

(xi)     SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGGCTTCTAG AATCAAGCGT AGTCTGGGAC GTCGTATGGG TACCTATCAT TTCTAAAAAT     60

6.      A process for producing a polypeptide comprising: expressing from the host cell of Claim 5 the polypeptide encoded by said DNA.

7.      A process for producing cells capable of expressing a polypeptide comprising transforming or transfecting the cells with the vector of Claim 4.

8.      A receptor polypeptide comprising a member selected from the group consisting of:
      (i) a polypeptide having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof; and
      (ii) a polypeptide encoded by the cDNA of ATCC Deposit No. 75899 and fragments, analogs and derivatives of said polypeptide.

9.      An antibody against the polypeptide of claim 8.

10.     A compound which activates the polypeptide of claim 8.

11.     A compound which inhibits activation the polypeptide of claim 8.

12.     A method for the treatment of a patient having need to activate a TNF receptor comprising: administering to the patient a therapeutically effective amount of the compound of claim 10.

13.     A method for the treatment of a patient having need to inhibit a TNF receptor comprising: administering to the patient a therapeutically effective amount of the compound of claim 11.

14.     The method of claim 12 wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said agonist and expressing said agonist *in vivo*.

15.     The method of claim 13 wherein said compound is a polypeptide and a therapeutically effective amount of the compound is administered by providing to the patient DNA encoding said antagonist and expressing said antagonist *in vivo*.

16.     A method for identifying compounds which bind to and activate the receptor polypeptide of claim 8 comprising:

        contacting a cell expressing on the surface thereof the receptor polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor polypeptide, with a compound under conditions sufficient to permit binding of the compound to the receptor polypeptide; and

        identifying if the compound is capable of receptor binding by detecting the signal produced by said second component.

17.     A method for identifying compounds which bind to and inhibit activation of the polypeptide of claim 8 comprising:

        contacting a cell expressing on the surface thereof the receptor polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor polypeptide, with an analytically detectable ligand known to bind to the receptor polypeptide

and a compound to be screened under conditions to permit binding to the receptor polypeptide; and

determining whether the compound inhibits activation of the polypeptide by detecting the absence of a signal generated from the interaction of the ligand with the polypeptide.

18.    A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 8 comprising:

determining a mutation in the nucleic acid sequence encoding said polypeptide.

19.    The polypeptide of Claim 8 wherein the polypeptide is a soluble fragment of the polypeptide and is capable of binding a ligand for the receptor.

20.    A diagnostic process comprising:

analyzing for the presence of the polypeptide of claim 19 in a sample derived from a host.